<p>Biodesix, Inc.（NASDAQ:BDSX - 获取免费报告）的股票在覆盖该股票的六家券商中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位分析师给予该股票卖出评级，一位给予持有评级，四位则对该公司给予买入评级。在过去一年中，对该股票发布评级的分析师的平均一年价格目标为 32.50 美元。</p>
<p>几位分析师对 BDSX 股票进行了评论。Weiss Ratings 在 12 月 15 日的研究报告中重申了对 Biodesix 股票的 “卖出（e+）” 评级。Canaccord Genuity Group 在 9 月 19 日的报告中设定了 Biodesix 的 20.00 美元价格目标，并给予该股票 “买入” 评级。最后，华尔街禅在 11 月 8 日的研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。</p>
<p><strong>查看我们对 Biodesix 的最新分析</strong></p>
<h2>机构资金流入和流出</h2>
<p>一些机构投资者和对冲基金最近调整了对 BDSX 的持股。Birchview Capital LP 在第一季度将其在 Biodesix 的持股增加了 2.8%。Birchview Capital LP 目前拥有 5,736,113 股该公司的股票，价值 3,586,000 美元，此前在上个季度增持了 154,937 股。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 目前拥有 205,647 股该公司的股票，价值 58,000 美元，此前在上个季度增持了 102,494 股。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 的新股份，价值 113,000 美元。最后，Millennium Management LLC 在第三季度收购了 Biodesix 的新股份，价值 113,000 美元。机构投资者和对冲基金持有该公司 20.96% 的股票。</p>
<h2>Biodesix 股票下跌 5.8%</h2>
<p>BDSX 股票周一开盘价为 6.69 美元。该公司的市值为 5325 万美元，市盈率为 -1.20，贝塔值为 0.62。该公司的流动比率为 1.84，速动比率为 1.84，债务股本比率为 41.11。该公司的 50 日移动平均价格为 7.41 美元，200 日移动平均价格为 7.33 美元。Biodesix 的 12 个月低点为 3.44 美元，12 个月高点为 32.20 美元。</p>
<p>Biodesix（NASDAQ:BDSX - 获取免费报告）最近于 11 月 3 日发布了季度财报。该公司报告的每股收益（EPS）为（1.16）美元，超出市场共识预期的（1.60）美元，超出幅度为 0.44 美元。该公司本季度的收入为 2177 万美元，而分析师的预期为 2098 万美元。Biodesix 的净利润率为负的 49.31%，股本回报率为负的 504.41%。研究分析师预测，Biodesix 在当前财政年度的每股收益将为 -0.35。</p>
<h2>关于 Biodesix</h2>
<p>（获取免费报告）</p>
<p>Biodesix, Inc 是一家总部位于科罗拉多州博尔德的商业阶段分子诊断公司，开发和提供基于血液的检测，以改善肺部疾病（包括肺癌）的诊断和管理。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性检测解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
<p>该公司的旗舰产品 VeriStrat® 是一种蛋白质组学检测，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>我不应该把这个发给你</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>黄金警报</li>
<li>比特币下跌，但你的收入即将暴涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
<p>在你考虑 Biodesix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Biodesix 并不在名单上。</p>
<p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BDSX

<p>Biodesix, Inc.（纳斯达克代码：BDSX）获得了六家券商的共识 “适度买入” 评级。该股票有一个卖出评级、一个持有评级和四个买入评级，平均一年目标价为 32.50 美元。机构投资者已调整其持股，其中 Birchview Capital LP 和 XTX Topco Ltd.的增持尤为显著。Biodesix 的股票开盘价为 6.69 美元，市值为 5325 万美元。该公司报告了上个季度超出预期的收益。Biodesix 专注于针对肺部疾病（包括肺癌）的血液检测</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus rating of &#34;Moderate Buy&#34; from the six brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>Biodesix, Inc.（NASDAQ:BDSX - 获取免费报告）的股票在覆盖该股票的六家券商中获得了 “适度买入” 的共识评级，MarketBeat.com 报道。一位分析师给予该股票卖出评级，一位给予持有评级，四位则对该公司给予买入评级。在过去一年中，对该股票发布评级的分析师的平均一年价格目标为 32.50 美元。</p>
</div><p>Several analysts have commented on BDSX shares. Weiss Ratings reaffirmed a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Monday, December 15th. Canaccord Genuity Group set a $20.00 price objective on Biodesix and gave the stock a &#34;buy&#34; rating in a report on Friday, September 19th. Finally, Wall Street Zen raised Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 8th.</p>
<div class="lb-trans"><p>几位分析师对 BDSX 股票进行了评论。Weiss Ratings 在 12 月 15 日的研究报告中重申了对 Biodesix 股票的 “卖出（e+）” 评级。Canaccord Genuity Group 在 9 月 19 日的报告中设定了 Biodesix 的 20.00 美元价格目标，并给予该股票 “买入” 评级。最后，华尔街禅在 11 月 8 日的研究报告中将 Biodesix 的评级从 “卖出” 上调至 “持有”。</p>
</div><p><strong>Check Out Our Latest Analysis on Biodesix</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Biodesix 的最新分析</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of institutional investors and hedge funds have recently modified their holdings of BDSX. Birchview Capital LP increased its position in shares of Biodesix by 2.8% in the first quarter. Birchview Capital LP now owns 5,736,113 shares of the company's stock worth $3,586,000 after acquiring an additional 154,937 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Biodesix by 99.4% during the 2nd quarter. XTX Topco Ltd now owns 205,647 shares of the company's stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Oracle Investment Management Inc. purchased a new stake in Biodesix during the 3rd quarter worth $113,000. Finally, Millennium Management LLC acquired a new stake in Biodesix in the 3rd quarter valued at $113,000. Institutional investors and hedge funds own 20.96% of the company's stock.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近调整了对 BDSX 的持股。Birchview Capital LP 在第一季度将其在 Biodesix 的持股增加了 2.8%。Birchview Capital LP 目前拥有 5,736,113 股该公司的股票，价值 3,586,000 美元，此前在上个季度增持了 154,937 股。XTX Topco Ltd 在第二季度将其在 Biodesix 的持股增加了 99.4%。XTX Topco Ltd 目前拥有 205,647 股该公司的股票，价值 58,000 美元，此前在上个季度增持了 102,494 股。Oracle Investment Management Inc. 在第三季度购买了 Biodesix 的新股份，价值 113,000 美元。最后，Millennium Management LLC 在第三季度收购了 Biodesix 的新股份，价值 113,000 美元。机构投资者和对冲基金持有该公司 20.96% 的股票。</p>
</div><h2>Biodesix Trading Down 5.8%</h2>
<div class="lb-trans"><h2>Biodesix 股票下跌 5.8%</h2>
</div><p>Shares of BDSX stock opened at $6.69 on Monday. The company has a market capitalization of $53.25 million, a price-to-earnings ratio of -1.20 and a beta of 0.62. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The firm has a 50-day moving average price of $7.41 and a 200 day moving average price of $7.33. Biodesix has a twelve month low of $3.44 and a twelve month high of $32.20.</p>
<div class="lb-trans"><p>BDSX 股票周一开盘价为 6.69 美元。该公司的市值为 5325 万美元，市盈率为 -1.20，贝塔值为 0.62。该公司的流动比率为 1.84，速动比率为 1.84，债务股本比率为 41.11。该公司的 50 日移动平均价格为 7.41 美元，200 日移动平均价格为 7.33 美元。Biodesix 的 12 个月低点为 3.44 美元，12 个月高点为 32.20 美元。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last released its quarterly earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.60) by $0.44. The company had revenue of $21.77 million for the quarter, compared to analysts' expectations of $20.98 million. Biodesix had a negative net margin of 49.31% and a negative return on equity of 504.41%. Research analysts forecast that Biodesix will post -0.35 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Biodesix（NASDAQ:BDSX - 获取免费报告）最近于 11 月 3 日发布了季度财报。该公司报告的每股收益（EPS）为（1.16）美元，超出市场共识预期的（1.60）美元，超出幅度为 0.44 美元。该公司本季度的收入为 2177 万美元，而分析师的预期为 2098 万美元。Biodesix 的净利润率为负的 49.31%，股本回报率为负的 504.41%。研究分析师预测，Biodesix 在当前财政年度的每股收益将为 -0.35。</p>
</div><h2>About Biodesix</h2>
<div class="lb-trans"><h2>关于 Biodesix</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.</p>
<div class="lb-trans"><p>Biodesix, Inc 是一家总部位于科罗拉多州博尔德的商业阶段分子诊断公司，开发和提供基于血液的检测，以改善肺部疾病（包括肺癌）的诊断和管理。该公司整合了先进的蛋白质组学和最近的基因组技术，提供旨在指导临床决策的非侵入性检测解决方案。Biodesix 运营着一家 CLIA 认证和 CAP 认可的实验室，能够大规模处理患者样本并保持严格的质量标准。</p>
</div><p>The company's flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.</p>
<div class="lb-trans"><p>该公司的旗舰产品 VeriStrat® 是一种蛋白质组学检测，将非小细胞肺癌患者分层为更可能从特定疗法中受益的组别。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>I Shouldn't Be Sending You This</li>
<li>Do not delete, read immediately</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>GOLD ALERT</li>
<li>Bitcoin is down but your income is about to explode</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Biodesix 更好</li>
<li>我不应该把这个发给你</li>
<li>请勿删除，立即阅读</li>
<li>100 万美元在退休后能维持多久？</li>
<li>黄金警报</li>
<li>比特币下跌，但你的收入即将暴涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Biodesix 吗？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Biodesix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Biodesix 并不在名单上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Biodesix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Biodesix, Inc.（NASDAQ:BDSX）被券商给予 “适度买入” 的平均评级